After graduating in Medicinal Chemistry and Technology at the University of Milan, Francesco Calzaferri obtained his PhD in Pharmacology at the University Autónoma of Madrid, funded by the ITC-Marie S. Curie “PurinesDX” programme. During his PhD he discovered new blood-brain barrier-permeable antagonists of the P2X7 receptor for the treatment of neurodegenerative and neurological disorders. He started working at the IBMM in 2021 in the group of Marie Lopez to develop novel drugs and chemical probes targeting epigenetic mechanisms for cancer treatment. In 2022 he was awarded a 3-year post-doctoral fellowship funded by the ARC Foundation to develop PROTAC-targeting DNA methyltransferases for multiple myeloma treatment. During his research experience, he visited several laboratories (IBEC in Barcelona, Ludwig Maximilians Universität in Munich, BSC laboratory in Strasbourg, and Janssen Cilag by Johnson and Johnson company in Toledo), which contributed to define his interdisciplinary experience in both chemistry and biology.